JAK2-IN-14
JAK2-IN-14 is an orally active JAK2 inhibitor with an IC50 of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over JAK1, JAK3, and TYK2, respectively. JAK2-IN-14 inhibits STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs) [1].
Product Specifications
CAS Number
[3087335-24-5]
UNSPSC
12352100
Target
Apoptosis; JAK; STAT
Related Pathways
Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Smiles
CC1=CN=C(NC2=CC=C(N3CCN(CC4CC4)CC3)C5=C2)N=C1C6=CN(CCCCO5)N=C6
Molecular Formula
C26H33N7O
Molecular Weight
459.59
References & Citations
[1]Qin S, et al. Discovery of Highly Selective and Potent Macrocyclic JAK2 Inhibitors for the Treatment of MPNs. J Med Chem. 2025 Aug 28;68 (16) :17933-17959.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK1; JAK2; JAK3; STAT5; Tyk2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
036077-HRP 200 µL
GLG1, CT (GLG1, CFR1, ESL1, MG160, Golgi apparatus protein 1, CFR-1, Cysteine-rich fibroblast growth factor receptor, E-selectin ligand 1, Golgi sialoglycoprotein MG-160) (Azide free) (HRP) discontinued
Ask
View Details 